Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 2/2001

Content (11 Articles)

Original Article

A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer

Ian Olver, Margaret Davy, Diana Lüftner, So-Hyang Park, Merrill Egorin, Andrew Ellis, Lorraine Webster

Original Article

Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients

Stefanie Reif, Dorothea Kingreen, Charlotte Kloft, Jenny Grimm, Wolfgang Siegert, Walter Schunack, Ulrich Jaehde

Original Article

Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model

Ping Guo, Jianguo Ma, Shaolan Li, Zhiwei Guo, Andrea L. Adams, James M. Gallo

Original Article

Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial

Roy S. Herbst, Cathleen Lynch, Michael Vasconcelles, Beverly A. Teicher, Gary Strauss, Anthony Elias, Ian Anderson, Patrick Zacarola, Nam H. Dang, Traci Leong, Ravi Salgia, Arthur T. Skarin

Original Article

Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein

Cecilia H. Fu, Sagrario Martin-Aragon, Kenneth I. Weinberg, Veronica C. Ardi, Peter V. Danenberg, Vassilios I. Avramis

Original Article

Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy

Omar N. Al Safarjalani, Xiao-Jian Zhou, Fardos N. Naguib, Naganna M. Goudgaon, Raymond F. Schinazi, Mahmoud H. el Kouni

Original Article

Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer

Koji Takeda, Shunichi Negoro, Nobuhide Takifuji, Takashi Nitta, Naruo Yoshimura, Kazuhiko Terakawa, Masahiro Fukuoka

Original Article

Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer

Pankaj Bhargava, John L. Marshall, Karen Fried, Marion Williams, Patricia Lefebvre, William Dahut, John Hanfelt, Edmund Gehan, Manuela Figuera, Michael J. Hawkins, Naiyer A. Rizvi

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine